Phage Therapy Polyclonal Bacteraemia Staphylococcus aureus

Staphylococcus aureus is a leading cause of bacteraemia and endocarditis in which intraclonal genetic variation, but not true polyclonal bacteraemia, is well documented. We describe a case of 36-year-old women with simultaneous and persistent bacteremia from two strains of Staphylococcus aureus that probably would have gone unrecognised because of the identical antibiotic profiles if had we not used bacteriophage susceptibility (“phage typing”) to further characterise the strains. In this patient, the dual bacteraemia was followed months later by another bacteraemia that likely would have been deemed a relapse of the original infection, except that we used similar methods to identify a third and unrelated strain. Our patient eventually responded well to antibiotics, and her bacteriophage therapy probably contributed little to that recovery. However, bacteriophage therapy required that we identify the strain of S. aureus causing her bacteraemia, and that requirement led directly to our identification of dual strains with identical antibiotic susceptibilities. Because of this experience, we alert other clinicians to the possibility of polyclonal infections with S. aureus. When bacteraemia is suspected, clinicians often pick a single colony or a few colonies from the original culture because prompt identification of the organism is critical and this practice provides a faster turnaround time. We caution that it might not identify different strains with different antibiotic sensitivities when polyclonal infections are present.

Annals of Internal Medicine
L-forms Antibiotic resistance Phages Escherichia coli

Bacterial L-forms require specialized culture techniques and are neither widely reported nor well understood in human infections. To date, most of the studies have been conducted on Gram-positive and stable L-form bacteria, which usually require mutagenesis or long-term passages for their generation. Here, using an adapted osmoprotective growth media, we provide evidence that pathogenic E. coli can efficiently switch to L-forms and back to a cell-walled state, proliferating aerobically in supratherapeutic concentrations of antibiotics targeting cell walls with few or no changes in their DNA sequences. Our work demonstrates that L-form switching is an effective adaptive strategy in stressful environments and can be expected to limit the efficacy of β-lactam and phages for many important infections.

Microbiology Spectrum
Phage biology Phage Therapy Phage-bacterium dynamics Antimicrobials

Bacteriophages (phages) are selective viral predators of bacteria. Abundant and ubiquitous in nature, phages can be used to treat bacterial infections (phage therapy), including refractory infections and those resistant to antibiotics. However, despite an abundance of anecdotal evidence of efficacy, significant hurdles remain before routine implementation of phage therapy into medical practice, including a dearth of robust clinical trial data. Phage–bacterium interactions are complex and diverse, characterized by co-evolution trajectories that are significantly influenced by the environments in which they occur (mammalian body sites, water, soil, etc.). An understanding of the molecular mechanisms underpinning these dynamics is essential for successful clinical translation. This review aims to cover key aspects of bacterium–phage interactions that affect bacterial killing by describing the most relevant published literature and detailing the current knowledge gaps most likely to influence therapeutic success.

EMBO Molecular Medicine
Online Course Phage therapy ESCMID ESGNTA

The first phage therapy course jointly organised by ESCMID (European Society of Clinical Microbiology and Infectious Diseases) and ESGNTA (ESCMID Study Group for Non-traditional Antibacterial Therapy) and includes four sessions with cutting-edge scientific talks in the field of personalised phage therapy : (1) therapeutic monitoring (2) immune response to bacteriophages (3) formulation and administration of bacteriophages for therapy, and (4) current state and prospects of oral phage therapy, followed by live Q&A sessions and panel discussion.

ESCMID Online Course 2022
News | August 31, 2022
Phage Therapy
Academics plan to roll out therapy widely in Australia: Researchers at the University of Sydney, Western Sydney Local Health District and the Westmead Institute for Medical Research are developing a therapeutic solution to antimicrobial resistance that predates the discovery and wide usage of antibiotics… [Link to Paper](https://www.escmid.org/fileadmin/src/media/PDFs/1Dates_Events/event_flyers/ESGNTA_Course22_web.pdf)
News | August 17, 2022
Phage Therapy
An expert team, led by Director of the Centre of Infectious Diseases and Microbiology at the Westmead Institute for Medical Research (WIMR) Professor Jon Iredell, is developing a key alternative to antibiotics and central to the treatment are phages…
Twitter | July 15, 2022
Phage Therapy
Twitter | July 05, 2022
FundingPhage Therapy
Publication | June, 2022
News | June 17, 2022 | Phage WA
Leading the fight against Antimicrobial Resistance (AMR) in Western Australia: The WA Phage website showcases the research journey and outputs of WA researchers from the Wal-yan Respiratory Research Centre at the Telethon Kids Institute. The Phage WA website connects us with our community and provides up to date information on our collective mission to tackle anti-microbial resistance (AMR) through phage therapy.
Publication | 2020
Phage TherapyClinical trialSepsis
Publication | February, 2021
Publication | January, 2020
AbstractPhage Therapy
Publication | January, 2021
AcinetobacterPhage-resistanceResearch paper
Publication | March, 2020
Phage isolationKlebsiellaPhage TherapyResearch paper
Publication | May, 2021
Publication | September, 2021
Publication | April, 2021
Phage biobankOpinion paper
Publication | November, 2020
PediatricsPhage TherapyClinical trialResearch paper
Publication | March, 2019
Phage TherapyResearch paper
Publication | May, 2021
Publication | May, 2021
Publication | July, 2020
Publication | September, 2021
Review paperRespiratory Tract infectionsPhage Therapy
Publication | August, 2021
Clinical trialPediatricsImmune responsePhage Therapy
Publication | December, 2020
Phage VirulenceAntibiotic synergyResearch paper
Publication | June, 2020
Cystic FibrosisPhage isolationPseudomonasStaphylococcusPediatrics
Publication | May, 2020
Publication | November, 2021
Phage host rangePseudomonasScreening assayResearch paper
Publication | April, 2020
Review paperPhage Therapy
Publication | August, 2021
KlebsiellaResearch paperPhage biology
Publication | October, 2021
Antibiotic resistanceStaphylococcusMRSA
Clinical Microbiology & Infection
Publication | October, 2021
Review paperPhage TherapyPediatrics
Publication | September, 2021
Phage biobank
Biopreservation and Biobanking
Publication | November, 2020
Publication | August, 2020
© 2023 Phage Australia